Angioplasty Balloons Market Research, Size Estimation, Growth Insights, Share Analysis, COVID-19 Impact and Overview By 2032

Angioplasty Balloons Market Highlights

Angioplasty Balloons Market size is anticipated to hold a value of USD 2.85 Billion by 2032 and is expected to register a CAGR of 4.9% during the assessment period of 2023 to 2032.

The Global Angioplasty Balloons Market trends is driven by several factors, such as technological advancements in balloons, increasing preference for minimally invasive procedures, surging prevalence of cardiac diseases, rising initiatives by public and private organizations to create awareness regarding angioplasty treatment options, increasing product launches and several clinical trials by the prominent players in the market. For instance, the European Atherosclerosis Society (EAS) creates awareness related to new developments and innovations to prevent atherosclerosis.

The Angioplasty Balloons Market is a dynamic and critical segment within the global healthcare industry. This market is characterized by innovative medical devices designed to treat coronary artery disease and other vascular conditions. Angioplasty balloons are inflatable catheter-based devices used to widen narrowed or blocked blood vessels, restoring blood flow and improving patient outcomes. As cardiovascular diseases continue to be a leading cause of morbidity and mortality worldwide, the demand for advanced angioplasty balloons is on the rise. This market is fueled by technological advancements, increasing aging populations, and a growing awareness of minimally invasive treatments. This introduction sets the stage for exploring the evolving landscape of the Angioplasty Balloons Market.

A lot of market players are dominating the global angioplasty balloons market. The prominent players are involved in strategic agreements, product launches and joint ventures to sustain their market positions. For instance, in August 2017, C.R. Bard, a part of Becton, Dickinson and Company, received US Food and Drug Administration (FDA) premarket approval for its Latonia drug-coated balloon to treat a new indication, stenosis in the arteriovenous (AV) fistulae of patients with end-stage renal disease.

Segmentation

The global angioplasty balloons market insights has been segmented based on type, application, and end user.

The market types of balloons used in angioplasty are normal balloons, cutting balloons, drug eluting balloons, and scoring balloons. The market, based on normal balloons, held a major share in 2018 owing to the widespread use and high preference rate. The drug eluting balloons segment is expected to be the fastest-growing segment during the forecast period due to the continued innovations by players.

The market, based on application, has been segmented into coronary artery disease and peripheral artery disease. The coronary artery disease segment held the largest share in 2019 owing to the increased cardiac cases across the globe, whereas the peripheral artery segment is anticipated to be the fastest-growing segment due to the increasing strategic initiatives by key players in this segment by prominent players.

The global angioplasty balloons market has been segmented, based on end user, into hospitals, cardiac catheterization laboratories, ambulatory surgical centers, and others.

The hospitals segment held the majority share of the market in 2019 owing to the increasing number of patient admissions due to cardiac diseases, whereas the cardiac catheterization laboratories segment is projected to be the fastest-growing segment during the study period owing to the increasing preference of these labs by medical professionals.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in 2019, owing to the high incidence rates of cardiac disorders, and strategic activities by major players in countries such as the US. The angioplasty balloons market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European angioplasty balloons market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The European market for angioplasty balloons is expected to hold a substantial share owing to the increase in the number of cardiac disorder cases. The angioplasty balloons market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The angioplasty balloons market in this region is anticipated to be the fastest growing during the forecast period due to the increasing uptake and adoption rate of newer treatment options by medical professionals. The increasing patient pool and mortality rate due to cardiac diseases in these countries also fuel the market growth. For instance, in 2017, ischemic heart disease was the second-highest cause for death in Japan. The angioplasty balloons market in the Middle East & Africa has been divided into the Middle East and Africa.

Key Players

The global angioplasty balloons market players are B. Braun Melsungen AG (Germany), Abbott (US), Biotronik SE & Co. KG (Germany), C.R. Bard (BD) (US), Boston Scientific Corporation (US), Cook (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), Terumo Medical Corporation (Japan), Cordis (Cardinal Health) (US), and Endocor (Germany).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Exploring the Transformative Potential of mixed reality in healthcare market

The mixed reality in healthcare market is expected to register a CAGR of 25.04% during the forecast period of 2022 to 2030, with an estimated market value of USD 9722.85 million in 2030. The field of healthcare is constantly evolving, driven by technological advancements that seek to improve patient care, enhance medical training, and streamline clinical workflows. One such innovation making significant waves in the industry is Mixed Reality (MR). Mixed Reality combines elements of the physical and virtual worlds to create immersive and interactive experiences, and its applications in healthcare are revolutionizing the sector in myriad ways. Mixed Reality Defined Mixed Reality is a fusion of both Augmented Reality (AR) and Virtual Reality (VR). While AR overlays digital information onto the real world, VR immerses users entirely into a computer-generated environment. MR, on the other hand, seamlessly blends these two experiences, allowing users to interact with virtual objects w...
Read more

Insulin Biosimilars Market Report, Key Trends, Competitive Scenario, Current and Future Players 2032

Insulin Biosimilars Market Highlights A disease in which the body’s ability to produce or respond to the hormone insulin is impaired, resulting in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood is termed diabetes. Biosimilar insulin is designed to be highly like the original, or reference, insulin product described in a patent. As patents for major branded insulin products start to expire, several biosimilar insulin markets are expected to launch in the coming years. According to MRFR analysis, Insulin Biosimilars Market size is expected to reach USD 1.68 billion by 2032 at a CAGR of 14.6% during the forecast period of 2023 to 2032. The USFDA approved new insulin glargine Basilar, for type 1 and type 2 diabetes which is a biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim’s biosimilar insulin glargine has got approval through the European Medicines Agency’s (EMA’s) Biosimilar p...
Read more

Leuprolide Acetate Market Share, Analysis and Projection, Region - Global Forecast to 2030

Market Scenario The leuprolide acetate market size is projected to reach USD 2,400 Million by 2030 at 10.50% CAGR during the forecast period 2022-2030. Leuprolide acetate is a medication used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty . The medication works by decreasing testosterone levels in men and estrogen levels in women . The report states that the increasing prevalence of prostate cancer and endometriosis is expected to drive the growth of the leuprolide acetate market in the projected timeframe . The report also highlights that side effects such as hot flashes, night sweats, decreased libido, erectile dysfunction, and osteoporosis associated with leuprolide acetate treatment are some factors which will likely act as market restraints for the growth of the leuprolide acetate market in the above mentioned projected timeframe . Key Players: GPI Golrang pharmaceutical investment (Russia), Bachem(Switzerland), avenit AG (...
Read more